首页> 外国专利> METHOD OF CORRECTING MICROCIRCULATION IN BONE TISSUE WITH COMBINATION OF L-NORVALIN AND ROSUVASTATIN IN CASE OF EXPERIMENTAL OSTEOPOROSIS AND FRACTURES AT ITS BACKGROUND

METHOD OF CORRECTING MICROCIRCULATION IN BONE TISSUE WITH COMBINATION OF L-NORVALIN AND ROSUVASTATIN IN CASE OF EXPERIMENTAL OSTEOPOROSIS AND FRACTURES AT ITS BACKGROUND

机译:在实验性骨质疏松症和骨折的情况下,结合L-降钙素和罗伐他汀纠正骨组织微循环的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to field of medicine and is intended for impact on microcirculation in bone tissue in case of experimental osteoporosis and fractures at its background. Method includes introduction of combination of pharmacological preparations to animal after modelling osteoporosis by means of bilateral ovariectomy and osteoporotic fractures of hip bone in female rats of Wistar line. As such preparations used is combination of L-norvalin in dose 10 mg/kg and rosuvastatin in dose 0.86 mg/kg, which is introduced to laboratory animal daily intragastrically one time per day at the background of osteoporosis modelling during eight weeks, and in case of fractures at the background of osteoporosis modelling during twelve weeks.;EFFECT: application of claimed invention results in synergism in positive impact on indices of microcirculation in bone tissue in case of osteoporosis and in bone callus in case of osteoporotic fractures.;1 ex
机译:技术领域本发明涉及医学领域,并且旨在在实验性骨质疏松症及其背景下的骨折的情况下对骨组织中的微循环产生影响。方法包括在Wistar系雌性大鼠中,通过双侧卵巢切除术和髋骨的骨质疏松性骨折对骨质疏松症进行建模后,向动物引入药物制剂的组合。如此使用的制剂是剂量为10 mg / kg的L-降冰片灵和剂量为0.86 mg / kg的瑞舒伐他汀的组合,在骨质疏松症建模的背景下,每天在胃内每天一次,在八周内引入实验动物,效果:在骨质疏松症建模背景下的十二周内发生骨折。效果:本发明的应用产生协同作用,对骨质疏松症和骨质疏松症骨折的骨组织中微循环指标产生积极影响。

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号